Last reviewed · How we verify

Ethypharm — Portfolio Competitive Intelligence Brief

Ethypharm pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Aristospan TRIAMCINOLONE HEXACETONIDE marketed Corticosteroid Glucocorticoid receptor Immunology 1969-01-01
Fentanyl Ethypharm Fentanyl Ethypharm phase 3 Opioid analgesic Mu-opioid receptor (OPRM1) Pain Management
Placebo (for baclofen) Placebo (for baclofen) phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University Hospital, Rouen · 2 shared drug classes
  2. GlaxoSmithKline · 2 shared drug classes
  3. Teva Branded Pharmaceutical Products R&D, Inc. · 2 shared drug classes
  4. University Hospital, Montpellier · 2 shared drug classes
  5. University of British Columbia · 2 shared drug classes
  6. Ain Shams University · 1 shared drug class
  7. AdventHealth · 1 shared drug class
  8. ANI Pharmaceuticals · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ethypharm:

Cite this brief

Drug Landscape (2026). Ethypharm — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ethypharm. Accessed 2026-05-13.

Related